Aarti Pharmalabs Ltd
Aarti Pharmalabs Limited manufactures Active Pharmaceutical Ingredients (API) and New Chemical Entities (NCE), API intermediates, Regulatory Starting Materials (RSM), Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and for commercial production.[1]
- Market Cap ₹ 3,299 Cr.
- Current Price ₹ 364
- High / Low ₹ 422 / 235
- Stock P/E 17.0
- Book Value ₹ 172
- Dividend Yield 0.00 %
- ROCE 16.1 %
- ROE 13.1 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 177 days to 141 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
0 | 1,200 | 1,945 | |
0 | 993 | 1,603 | |
Operating Profit | 0 | 207 | 342 |
OPM % | 17% | 18% | |
0 | 3 | 2 | |
Interest | 0 | 12 | 21 |
Depreciation | 0 | 42 | 63 |
Profit before tax | 0 | 155 | 261 |
Tax % | 21% | 26% | |
Net Profit | 0 | 122 | 193 |
EPS in Rs | 21.35 | ||
Dividend Payout % | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 62% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 58% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
0 | 0 | 45 | |
Reserves | -0 | 1,386 | 1,513 |
0 | 338 | 214 | |
0 | 315 | 458 | |
Total Liabilities | 0 | 2,040 | 2,231 |
0 | 782 | 966 | |
CWIP | 0 | 187 | 62 |
Investments | 0 | 32 | 74 |
0 | 1,038 | 1,130 | |
Total Assets | 0 | 2,040 | 2,231 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
0 | -44 | 263 | |
0 | -139 | -158 | |
0 | 260 | -163 | |
Net Cash Flow | 0 | 78 | -58 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|
Debtor Days | 115 | 83 | |
Inventory Days | 272 | 188 | |
Days Payable | 123 | 108 | |
Cash Conversion Cycle | 264 | 162 | |
Working Capital Days | 214 | 141 | |
ROCE % | 19% | 16% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Secretarial Compliance Report for the financial year ended March 31, 2023.
- Related Party Transactions For The Half Year Ended March 31, 2023. 15 May
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 May - Listing Regulations, we hereby enclose Newspaper Publication of Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2023
- Related Party Transaction For The Half Year Ended March 31, 2023. 12 May
- Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 12 May
Annual reports
No data available.